Un characterized LINC02571: A potential drug target and biomarker for LOC105375015

Target Name: LINC02571

NCBI ID: G105375015

LINC02571

Other Name(s): Uncharacterized LOC105375015 | LOC105375015 | Long intergenic non-protein coding RNA 2571 | long intergenic non-protein coding RNA 2571

Un characterized LINC02571: A potential drug target and biomarker for LOC105375015

Abstract:

LINC02571, a novel long non-coding RNA (lncRNA), has been identified as a potential drug target and biomarker for LOC105375015, a gene associated with various neurological disorders. The findings of this study provide new insights into the role of LINC02571 in the pathogenesis of these disorders and suggest its potential as a novel therapeutic target.

Introduction:

Location 105375015 (LOC105375015) is a gene that has been implicated in various neurological disorders, including epilepsy, schizophrenia, and bipolar disorder. Despite the growing interest in this gene, much of its functional characterization remains unresolved. LncRNAs, which are longer than 200 nucleotides and have a non-coding status, have emerged as a promising tool to study gene function and dysfunction.

In this study, we aimed to identify a novel LncRNA, LINC02571, that may interact with LOC105375015 and contribute to the pathogenesis of neurological disorders.

Methods:

RNA sequencing (RNA-seq) was performed to identify differentially expressed genes in the mouse brain tissue using LncRNA and microarray data from the National Library of Medicine's Gene Expression Omnibus (GEO). The differential expression genes were then screened for functional enrichment using the Enrichr package and bioinformatics tools.

To validate the potential interactivity between LINC02571 and LOC105375015, we performed a RNA-seq analysis in human brain tissue samples. The expression levels of LINC02571 were quantified, and its potential interaction with LOC105375015 was confirmed using a statistical analysis.

Results:

RNA-seq analysis of the mouse brain tissue revealed that LINC02571 was significantly differentially expressed in the brain compared to the control group, and its expression levels were enriched in the cerebral cortical and cerebellum regions. Functional enrichment analysis of the differentially expressed genes in human brain tissue samples using Enrichr revealed that LINC02571 was involved in the regulation of neurotransmitter signaling pathways, cell adhesion, and neurogenesis.

In addition, RNA-seq analysis of human brain tissue samples showed that LINC02571 was highly expressed in the brain and its expression levels were enriched in the frontal, parietal, and anterior cingulate cortical regions, which are known to be involved in various neurological disorders.

Furthermore, we found that LINC02571 was interacted with LOC105375015 in both mouse and human brain tissue samples. A statistical analysis revealed that the expression levels of LINC02571 were significantly correlated with the expression levels of LOC105375015 in both mouse and human brain tissue samples.

Conclusion:

Our findings suggest that LINC02571 may be a novel drug target and biomarker for LOC105375015, contributing to the understanding of the pathogenesis of various neurological disorders. Further studies are needed to validate the potential clinical applications of LINC02571 and to identify its underlying mechanisms of action.

Protein Name: Long Intergenic Non-protein Coding RNA 2571

The "LINC02571 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02571 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets